


# Reference guide

January 2026



# Table of contents

This document contains interactive elements.  
Use the table of contents on this page and the arrows  
on each page to navigate through the sections.




**1**  
**Welcome to LeapSpace**

**2**  
**Core features**

**3**  
**Core content**

# Welcome to LeapSpace



# Welcome to LeapSpace

Research-Grade AI-Assisted Workspace built on trusted science

LeapSpace™, Elsevier’s research-grade, AI-assisted workspace. Built on the world’s most comprehensive collection of scientific content, LeapSpace helps academic and corporate researchers uncover deeper insights, accelerate innovation, and collaborate seamlessly in one secure environment. It combines multimodel responsible AI with transparency and clear trust markers, Enterprise-grade data privacy and security, so that every insight is designed to be explainable, traceable, and grounded in the high quality global science.

## Who is this guide for?

Users across R&D teams who use LeapSpace day-to-day to explore evidence, accelerate discovery and collaborate with confidence in one secure environment.

## Drive faster insights and impact across sectors

- **Industry:** Pharma and biotech, MedTech, engineering, energy, chemicals, technology and more
- **Academic and government:** Leading universities, government agencies, research labs and beyond

**Get started**

Register | Sign in

## How to use this guide?

### Start with core features

- Learn how to choose Standard search or Deep research, read Copilot steps and verify results using References and Trust Cards

### Understand core content

- Learn the difference between publisher neutral -publisher Scopus records and full text, which evidence objects respond which questions and when to escalate from abstracts to methods

### Build research workflows

- Follow the step by step pages for core workflows: explore a topic, find collaborators, find funding

### Use resources

- Use the micro-videos for context, then follow links to guides, articles, support hub, and more



### Corporate innovation needs trust you can test

Privacy, traceability, and decision advantage through verification



### Designed to sharpen critical thinking

Shows uncertainty, contradictions and what to try next



# What sets LeapSpace apart?



1

**High quality content:**

A publisher-neutral AI tool uniting full-text and abstracts offering unmatched content depth and breadth, updated daily.



2

**Trust Cards:**

Our Trust Cards show sources, surface contradictions and help researchers calibrate the strength of the evidence.



3

**Transparency and trust**

All responses are grounded exclusively in research-grade data with humans in the loop to maintain quality & integrity.



4

**Purpose-built for research:**

Rapidly surfaces hidden connections and gaps using agentic AI to tackle complex, open and interdisciplinary questions.



5

**Versatile AI workspace:**

Consolidates a wide range of research tasks into a single workspace, freeing up more time for discovery and critical thinking.




6


**Enterprise-grade privacy and security:**

Everything you do in LeapSpace is [private](#), [secure](#), and encrypted and we never use your data to train any LLMs. Learn more about [how Elsevier ensures privacy and security every step of the way](#).

# How LeapSpace works



# Core features



# Select your operating mode: Standard search or Deep research

LeapSpace is built on Elsevier's deep expertise and combines quality scientific information and data with innovative technologies to deliver insights that help researchers advance outcomes

## Standard search

### Fast, planned research pass that produces a referenced response

Standard search uses Copilot<sup>1</sup> as an agentic planner. It then runs hybrid retrieval (semantic + keyword).

- **Use when:** quick orientation, evidence triage, quick comparisons, claim checking
- **Output:** referenced response with summary, confidence level, linked citations for a decision-ready brief
- **Verify:** open citations → Reference details → Trust Cards → open abstracts or full text

## Deep research

### Complex research that produces a referenced comprehensive report

Deep research begins with intent and planning. Parallel agents search, read, reflect and plan. Meta-analysis surfaces overlaps, contradictions and gaps. A writing agent creates a report with evidence, confidence and uncertainty.

- **Use when:** complex, cross-disciplinary, high-stakes questions, due diligence
- **Output:** multi-page report with scope, assumptions, limitations and evidence for decision-ready reuse
- **Verify:** scope, assumptions, limitations → Reference details → Trust Cards → open abstracts or full text

Standard search and Deep research show steps and linked citations. Use Reference details and Trust Cards to verify passages. Find collaborators and Find funding can be starting points or follow-up questions.

<sup>1</sup>Copilot in LeapSpace is Elsevier Copilot, not Microsoft Copilot.

# Ask in natural language

Get inspired with industry prompts you can copy paste to see how it produces structured results fast

Market segments	<input type="radio"/> Standard search		<input checked="" type="radio"/> Deep research	
	Use case	Prompt	Use case	Prompt
Engineering	Rapid evidence scan for motor-driven system efficiency upgrades (process plants)	motor efficiency upgrades for process plants	CAPEX retrofit decision brief for motor-driven systems (savings + reliability trade-offs)	We're planning motor system retrofits. Which interventions deliver the highest measured efficiency gains and what are the reliability trade-off in real plants?
Energy	Pipeline flow-assurance triage for asphaltene deposition (mitigation options + Shortlist collaborators / KOL)	Our pipelines are seeing asphaltene build-up. What mitigation actually work in the field under comparable conditions?	Energy-transition technology scouting brief (shortlist + decision-ready evidence package)	We're scouting low-carbon hydrogen pathways. Compare leading options since 2019: performance ranges, cost drivers, TRL, key bottlenecks, and where the evidence is strongest. Produce a shortlist with citations
Chemicals & Materials	Evidence review for PFAS impact on vegetable cultivation	PFAS in soil/irrigation: impact on vegetable yield and PFAS uptake?	Broader exploration and evidence review for PFAS impact on vegetable cultivation	Vegetables exposed to PFAS: which tissues accumulate the most, what mechanisms drive growth impacts, and what mitigation approaches have evidence? Structured report + limitations + citations
Technology	Reliability risk scan for semiconductors/power electronics (design constraints + standards)	SiC MOSFET inverter reliability: failure modes + mitigations (EV/industrial drives)	Systematic review + architecture trade-offs (DC grids / MVDC)	Solid-state circuit breakers for DC microgrids/MVDC: top architectures and trade-offs (interruption, losses, coordination, standards). Design-review brief + citations
Pharma & Biotech	Evidence triage for target and modality decisions (discovery)	[Target/pathway] in [indication]"which modalities look most promising and what are the red flags?	Decision brief for indication expansion / repurposing	Anti-inflammatory repurposing for Parkinson's progression: which existing drugs have the strongest evidence, why, and what are the key limitations? Decision brief + citations
Medtech	SOTA scan of current devices + clinical benchmarks (for clinical indication device function)	Benchmarks for [device type] in [indication] (performance + safety ranges)	Clinical evaluation brief for device adoption (benefit + harm + workflow trade-offs)	Evaluating AI-assisted colonoscopy (CADE): impact on ADR, false positives, procedure time and adverse events; where does it not generalize? Adoption brief + citations

 [Download LeapSpace Use Cases and Prompt guide](#) – Explore cross-industry examples and peer-proven starter prompts for Standard Search and Deep Research.



# Standard search

*“In my early experience with LeapSpace, I’m impressed by how it helps shorten the time spent on cross-checking references for regulatory readiness and broader research needs. With clickable sources and clearly structured tables, it saves users time when sharing reports and streamlines workflows. LeapSpace stands apart from general AI tools as it is built on peer-reviewed scientific content and is designed to support research, not generic queries. For teams under pressure to deliver well-supported evidence, LeapSpace advances rigor and transparency by providing traceable citations in its responses.”*

**Victoria Ball**

Associate Director, Global Library Services,  
Incyte, United States

Standard search

<b>Overview</b>	Copilot steps	Referenced response	Show all references	Reference details and Trust Cards	Find collaborators	Find funding	Export referenced response
-----------------	---------------	---------------------	---------------------	-----------------------------------	--------------------	--------------	----------------------------

# Rapid synthesis you can verify

Copilot shows its steps as it searches Scopus records and full text to produce a cited synthesis

**Standard search:** Copilot is an agentic planner that decomposes your question and runs hybrid retrieval (semantic plus keyword) across Scopus records and full text. It returns a referenced response with linked citations.

Use it to orient quickly, then narrow only where evidence demands it. For R&D teams, linked citations and Trust Cards cut cross-checking time and keep reuse traceable in briefs, protocols and review notes.

## Workflow

- Ask your question in natural language (e.g. Explore a topic, find collaborators or funding)
- Add constraints when needed (time range, domain, geography)
- Review Copilot Steps
- Verify: Show all references → Reference details → Trust Cards; open full text for methods and limits
- Use Conversation history to resume prior work
- Use Temporary conversations to avoid saving history, if needed

**Discover *deeper* insights**  
Powered by Scopus data and ScienceDirect full-text

What are the latest findings on GLP-1 receptor agonists for weight management beyond diabetes?

Deep Research ↑

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Steer retrieval with one constraint, then verify one claim before expanding.



[See Standard search in action](#)

Standard search

Overview	<b>Copilot steps</b>	Referenced response	Show all references	Reference details and Trust Cards	Find collaborators	Find funding	Export referenced response
----------	----------------------	---------------------	---------------------	-----------------------------------	--------------------	--------------	----------------------------

# How the synthesis is built

Copilot Steps shows the plan and searches behind each synthesis, with links back to the sources

Copilot is an agentic planner: it decomposes questions and runs hybrid retrieval (semantic plus keyword) across Scopus records and available full text to compose a cited synthesis. Copilot Steps exposes the plan and searches executed

For R&D teams, this can help turn speed into defensibility. Copilot Steps and linked citations support critical thinking by keeping sources, scope, and evidence alignment visible before reuse.

## Workflow

- Run a Standard search query
- Open Copilot Steps while it runs
- Review the plan, sub-questions, and search types
- Refine: add one constraint and rerun
- Verify: open citations and Trust Cards; open full text for methods and limits

The screenshot displays a search plan for the query: "What are the latest findings on GLP-1 receptor agonists for weight management beyond diabetes? could also work?". The plan is organized into three main steps:

- Creating a plan to respond to your query**
- Performing natural language search**: Using data from Scopus, the search question is refined to "What are the recent findings (2024-2026) on the efficacy, safety, and mechanisms of GLP-1 receptor agonists for weight management in non-diabetic populations?". A filter for "Publication years: 2024..." is applied.
- Performing keyword search**: Using data from Scopus, a complex Boolean query is generated: ("GLP-1 receptor agonist" OR semaglutide OR liraglutide OR dulaglutide OR tirzepatide) AND ("weight management" OR "weight loss" OR obesity OR "body weight") AND (efficacy OR effectiveness OR safety OR adverse OR mechanism\* OR pharmacology) AND (nondiabetic OR "non-diabetic" OR "without diabetes"). A filter for "Publication years: 2024..." is applied.

Below the keyword search, another natural language search step is shown, refining the question to "How do recent studies (2024-2026) describe the efficacy, safety, and mechanisms of GLP-1 receptor agonists for weight management in non-diabetic populations?". A filter for "Publication years: 2024..." is applied. A final keyword search step shows a refined Boolean query: ("GLP-1 receptor agonist" OR semaglutide OR liraglutide OR dulaglutide OR tirzepatide) AND ("weight management" OR "weight loss" OR obesity OR "body weight") AND (efficacy OR effectiveness OR safety OR adverse OR mechanism\* OR pharmacodynamic\* OR pharmacokinetic\*) AND (nondiabetic OR "non-diabetic" OR "without diabetes") AND (method\* OR protocol OR "adverse event\*" OR "mechanism of action" OR "clinical trial" OR "results show"). A filter for "Publication years: 2024..." is applied.

*Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.*



### Power user tip

Capture query terms in Copilot Steps, then verify one claim before expanding.



### Transparency by design

Steps are shown in real time, and referenced insights can be traced back to original sources.

Standard search

- Overview
- Copilot steps
- Referenced response**
- Show all references
- Reference details and Trust Cards
- Find collaborators
- Find funding
- Export referenced response

# Structured, referenced response

Grounded in peer-reviewed, publisher-neutral sources with traceable citations

Referenced response: Copilot composes a structured response from Scopus records and available full text, linking citations to key statements. Open any citation to inspect the supporting passage in Reference details and Trust Cards.

Built for reuse in briefs, protocols and review notes: structure reduces scan time and keeps claims traceable. If a Confidence level appears, treat it as a cue and verify in sources.

## Workflow

- Scan the topic overview and summary table for the claims you need
- Open an inline citation → Reference details → Trust Cards (supporting passage)
- Use Show all references to check coverage
- Open full text for methods/limits ; use abstract for screening.
- Follow up to narrow one sub-question or add constraints

**GLP-1 receptor agonists for weight management**

Latest Findings on GLP-1 Receptor Agonists for Weight Management Beyond Diabetes

Recent (2024–2026) evidence shows that **GLP-1 receptor agonists (GLP-1RA)**—originally developed for type 2 diabetes—are now firmly established as effective pharmacologic options for weight management in **non-diabetic overweight and obese populations**.

Efficacy in Non-Diabetic Adults

- **Significant weight loss:** Meta-analyses report mean reductions of **-8.7 kg** and BMI decreases of **-3 kg/m<sup>2</sup>** in non-diabetic individuals with obesity [1] [2].
- **Cardiometabolic benefits:** Improvements in systolic BP (−4.1 mmHg), diastolic BP (−1.4 mmHg), and lipid profiles (↓LDL-C, TC, TG; ↑HDL-C) [1] [2].
- **Drug comparisons:**
  - **Semaglutide** generally outperforms liraglutide in weight and cardiometabolic outcomes [3].
  - **Tirzepatide** (GLP-1/GIP dual agonist) shows the most pronounced effects on weight and BP reduction [1] [4].
  - **Retatrutide** (GLP-1/GIP/glucagon triple agonist) and **survodutide** (GLP-1/glucagon dual agonist) demonstrate superior weight loss in trials, with >15% reductions in many participants [4] [5].

Durability and Discontinuation Effects

- **Metabolic rebound:** Discontinuation leads to **clinically significant reversal** of benefits—weight regain, increased BP, and worsened glycaemic control—especially with longer follow-up and semaglutide use [6].
- **Real-world adherence:** Weight loss in practice is often less than in trials due to lower dosing and high discontinuation rates (20–50% in first year) [7].

Safety Profile

- **Common adverse events:** Gastrointestinal symptoms (nausea, vomiting) are most frequent; hypoglycemia risk is low in non-diabetics [1] [2].
- **Emerging concerns:**
  - **Neuropsychiatric:** Semaglutide shows a signal for depressive disorders; liraglutide and tirzepatide do not [8].
  - **Rare events:** Possible associations with pancreatitis, thyroid cancer/dysfunction, acute nephritis, and certain eye disorders (e.g., retinopathy, retinal hemorrhage) [9] [10].
  - **Surgical/anaesthesia considerations:** Delayed gastric emptying may increase aspiration risk, though incidence is rare [11].
  - **Dermatologic/aesthetic:** Rapid weight loss may cause skin laxity, facial volume loss, and wound healing issues [12].

Mechanisms Beyond Glycemic Control

- **Primary weight loss drivers:** Delayed gastric emptying, increased satiety, reduced appetite and cravings via neurohumoral pathways [13] [14].
- **Additional benefits:** Anti-inflammatory and immunomodulatory effects may support conditions like psoriasis [4] [15].

Summary Table: Key Findings in Non-Diabetic Weight Management

Aspect	Findings	Notable Agents	Citations
<b>Weight Loss</b>	-8-15% reduction; superior with dual/triple agonists	Semaglutide, Tirzepatide, Retatrutide, Survodutide	[1] [2] [4] [5]
<b>Cardiometabolic</b>	↓BP, improved lipid profile	All GLP-1RA; Tirzepatide strongest	[1] [2]
<b>Durability</b>	Rebound after cessation	Semaglutide > Liraglutide rebound severity	[6]
<b>Safety</b>	GI events common; rare serious risks	Semaglutide (depression signal), others	[1] [8] [9] [10]
<b>Mechanism</b>	Satiety, delayed gastric emptying	Class-wide	[13] [14]

**Confidence level:** High for efficacy and common adverse events (supported by multiple meta-analyses); Moderate for rare/emerging safety signals (based on pharmacovigilance and observational data).

Show all 14 references [14] [15]

Follow-up Suggestions

- ↳ What mechanisms do GLP-1 receptor agonists utilize for appetite regulation in non-diabetic populations?
- ↳ How do GLP-1 receptor agonists impact metabolic health in individuals without diabetes?
- ↳ What are the long-term effects of GLP-1 receptor agonists on weight loss maintenance?

Ask a follow-up question

LeapSpace is powered by Scopus and ScienceDirect. AI responses may vary in quality. [Share feedback](#)

*Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.*



### Power user tip

Open Elsevier full text for methods/limits to use Reading Assistant/Compare Experiments); use abstract for screening.



How to access Reading Assistant and Compare Experiments from LeapSpace



Reclaim time for big ideas  
See how LeapSpace supports trusted, source-linked literature review

Standard search

- Overview
- Copilot steps
- Referenced response
- Show all references**
- Reference details and Trust Cards
- Find collaborators
- Find funding
- Export referenced response

# Show all references

Review the full evidence set behind a referenced response, then drill down to inspect sources

Show all references opens the full list of sources used in the referenced response. Each item links to Reference details so you can inspect excerpts, abstracts, and available full text.

This is fast due diligence for reuse: check coverage, spot missing perspectives, and decide what to open before you quote a claim in a brief, protocol, or review note. Use it to reduce cherry-picking and keep evidence selection traceable.

## Workflow

- Click Show all references to open the All references panel
- Scan the list to confirm breadth and relevance
- Open 1-3 central sources first (Reference details)
- Open full text for methods/limits; abstract for screening

The screenshot displays the LeapSpace interface for a search on "GLP-1 receptor agonists for weight management". On the left, a table lists various outcomes and their associated evidence. On the right, a detailed view of a reference is shown, including its title, authors, and abstract.

Outcome	Value	Category	Count
BP reduction	SBP ↓ -4 mmHg; DBP ↓ -1.4 mmHg	Consistent across agents	1   2
Lipid profile	LDL, TC, TG ↓; HDL ↑	Cardioprotective	1   2
GI adverse events	47-84% incidence	Most common side effect	3
Discontinuation	20-50% in 1st year	Real-world data	3
Rebound post-cessation	Significant weight & BP regain	Greater with semaglutide	3
CV & renal outcomes	HR 0.76 (MACE), HR 0.64 (MAKE)	vs. other AOMs	11

**Confidence Level: High** — Multiple large RCTs, meta-analyses, and real-world studies consistently support efficacy and safety patterns, though long-term safety and rebound effects require further study.

If you'd like, I can next **compare GLP-1 RAs with other emerging anti-obesity drugs** to highlight relative benefits and risks. Would you like me to prepare that comparison?

Follow up Suggestions:

- What mechanisms do GLP-1 receptor agonists use to promote weight loss in non-diabetic populations?
- How do GLP-1 receptor agonists impact appetite regulation and satiety?

Ask a follow-up question

LeapSpace is powered by Scopus and ScienceDirect. AI responses may vary in quality. [Share feedback](#)

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Open one source that supports the main claim and one that frames limits or alternatives.

# Inspect the source behind a claim

Reference details and Trust Cards connect each claim to the cited passage through link to statement

Inline citations open Reference details (source info, Excerpt, Abstract, View full text). Trust Cards add “Link to statement” to map each claim to the cited passage.

For corporate R&D, this makes traceability usable: confirm support, spot when evidence is insufficient, and adjust wording before reuse in briefs, protocols, and review notes. Trust Cards explain why a source was cited and can highlight contradictions to help calibrate evidence strength.

## Workflow

- Click an inline citation to open Reference details
- Review source info; use View full text when needed
- Read Trust Card “Link to statement”
- Full text: Inspect Excerpt; Abstract: use for quick context
- If support is limited or mixed, open another source before reuse

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Verify the claim and the sentence that limits it (method, population, timeframe) before you share.



Move from insight to action with confidence

Trust Cards validation in one click.

Standard search

- Overview
- Copilot steps
- Referenced response
- Show all references
- Reference details and Trust Cards
- Find collaborators**
- Find funding
- Export referenced response

# Find collaborators

Topical author finder uses vector search on Scopus author profiles to identify topic-aligned researchers

Find collaborators runs Topical author finder / Author Search: vector search over Scopus author profiles built from an author's published work to surface researchers aligned to your query, not just keywords.

Action, not just responses: move from a topic to a defensible shortlist for partnership, expert review, or KOL mapping. Verify relevance via matching documents before outreach and use constraints to fit compliance and stakeholder scrutiny.

## Workflow

- Ask: Who are the most relevant researchers for [topic]?
- Review active contributors (and clusters if shown)
- Open Author preview; check matching documents for topical fit
- View profile to confirm affiliations and recent publications
- Refine with constraints (country, publication count, h-index) when needed

**GLP-1 receptor agonists for weight management**

Pioneers in obesity and metabolic research

Leading Researchers in Related Fields to GLP-1RA Weight Management

Based on the latest data, several researchers are pioneering work in **GLP-1 receptor agonists, incretin-based therapies, and novel pharmacologic approaches for obesity**—closely related to the field of weight management beyond diabetes.

Researcher	Affiliation	Focus Areas	Key Contributions	Citations
<b>Patrick J. Knerr</b>	Novo Nordisk Inc., USA	GLP-1/GIP/glucagon tri-agonists, biased signaling	Developed NN706 tri-agonists; optimized GLP-1 analogues for weight loss	1,921
<b>Gerald Grandt</b>	Heinrich-Zentrum München, Germany	Anti-obesity drug discovery, gut peptide agonism	Comparative studies on tirzapatide vs semaglutide; Nature Reviews Drug Discovery work	1,342
<b>Dimitris Papamargaritis</b>	College of Life Sciences, UK	GLP-1RA mechanisms, cardiometabolic continuum	GLP-1-directed NMDA receptor antagonism; EASD/ADA consensus reports	1,787
<b>Jonathan D. Douros</b>	Novo Nordisk Inc., USA	Emerging obesity pharmacotherapies	Pipeline analysis for future anti-obesity drugs; mitochondrial function effects of GLP-1RAs	1,712
<b>Anish A. Konkar</b>	Pharma Research & Early Development, Switzerland	Peptide therapeutics, triagonists	Rational design of monomeric peptide triagonists; SAR441288 trials	2,983
<b>Anne Leutenbach</b>	Endokrinologie und Diabetologie, Germany	GLP-1 single-/dual/triple agonists	Narrative reviews, real-world liraglutide effectiveness studies	484
<b>Volkan D. Yumuk</b>	Istanbul University-Cerrahpasa, Turkey	Incretin pharmacotherapy, global obesity epidemiology	NEJM semaglutide trials; Nature Reviews Endocrinology obesity overview	6,632
<b>Paul Faraján</b>	Hellenic Medical Association for Obesity, Greece	Triple agonism, obesity therapies	Reviews on emerging pharmacotherapies; pediatric obesity studies	684
<b>Nasreen F. Alfaris</b>	Endocrine & Metabolism	Incretin combinations, diet	Systematic reviews on incretin combos;	1,629

**Author preview: Patrick J. Knerr**

Matching documents: 31 | h-index: 20 | Citations: 1,921

**Matching documents:**

- Acute exogenous acyl-GIP treatment enhances lipid handling and fatty acid oxidation by involving brown fat  
Lyons, S.A. et al. *Nature Metabolism*, 2025, 7, 6, 1263-1296.
- A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice  
Douros, J.D. et al. *Nature Metabolism*, 2025, 7, 6, 1263-1296.
- The Promise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs  
Douros, J.D. et al. *Journal of Clinical Medicine*, 2025.
- Correction to: GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice  
Gudgesell, M.M. et al. *Nature Metabolism*, 2025, 7, 6, 1263-1296.
- GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice  
Gudgesell, M.M. et al. *Nature Metabolism*, 2025.

*Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.*



### Power user tip

Constrain by last 5 years + one region first, then verify 1-2 matching documents per shortlisted author before expanding.



### Find collaborators 30-sec video

Turn insight into action.

Standard search

- Overview
- Copilot steps
- Referenced response
- Show all references
- Reference details and Trust Cards
- Find collaborators
- Find funding**
- Export referenced response

# Find funding

Match your topic to curated funding opportunities, with a Funding preview panel and links to the funder

Find funding runs over Funding Institutional and returns a structured table of opportunities. Open Funding preview to review key fields and follow the link to the award page on the funder site.

Turn insight into action: identify programs to join, co-funding options, and partner targets, then package a defensible business case. Funding calls change, so treat the funder page as the source of record before acting.

## Workflow

- Ask “What funding opportunities fit this topic?”
- Add a region or country when needed
- Scan the table (opportunity, funder, amount, eligibility, location)
- Open Funding preview for details
- Open the award page on the funder site to verify eligibility
- Shortlist and refine with one constraint at a time

The screenshot displays the LeapSpace interface for finding funding. The search topic is 'GLP-1 receptor agonists for weight management'. The results show a table of funding opportunities and a detailed preview for one opportunity.

Opportunity	Funder	Amount	Collaboration Scope	Eligibility	Citations
Notification of intent: Diet and health: collaborative R&D grants	Biotechnology and Biological Sciences Research Council (BBSRC) & Defra	\$995,200 USD	Builds partnerships between academia & industry to co-develop novel food products and innovations for healthy, sustainable diets	UK HEIs, research council institutes, UKRI-approved independent research organisations, public sector bodies	27
Advancing Technologies to Enhance Engagement in Cell Therapy for T1D	JDRF	\$300,000 USD	Supports industry-academia collaborations to improve engraftment of insulin-producing cells at extrahepatic sites	Non-profit, for-profit, universities, hospitals, labs, eligible government agencies	28
Beyond Pediatrics: Advancing Early Detection in Adult-Onset T1D	JDRF	\$900,000 USD	Encourages corporate-university partnerships to improve early diagnosis in adult-onset T1D	Non-profit, for-profit, universities, hospitals, labs	29
FY25 Innovative Awards	JDRF	\$200,000 USD	Seed funding for high-risk, high-reward research with potential paradigm shifts; open to industry	Faculty-level researchers in eligible institutions	30

The funding preview panel for 'Notification of intent: Diet and health: collaborative research and development grants' includes the following details:

- Aim:** The joint funding opportunity provided by BBSRC and Defra aims to build and strengthen partnerships between academia and industry and enable the co-development of collaborative research and development projects that develop novel food products and innovations to deliver healthy, sustainable, and resilient diets for the UK population. For more information on the background of this opportunity and the Good Food Cycle, go to the Additional Information section.
- Scope:** You are invited to submit proposals for collaborative research and development projects, that explore the following and support the 'Good Food Cycle'. Projects should address one or more of the following priority areas:
  - Improving the nutrition of food and drink products to support populations at higher risk of malnutrition, muscle loss or both, for example those using GLP-1 drugs, older population groups and those from disadvantaged socio-economic backgrounds
  - Supporting research and innovation to assess the impact of food processing and final food product composition on health, including but not restricted to assessing and improving the nutritive value retained by different processing methods, as well as evaluating the impact of food additives and emulsifiers on human physiology, to develop innovations and sustainable alternatives to support healthy sustainable diets
  - Improving environmental outcomes for novel innovations in the food and drink sector for example by considering a circular economy approach seeking to reduce waste and food losses

To address these themes, your project can focus on one or more of the following:



### Power user tip

Start with one region + one funding type, then verify eligibility before you expand.



### Find funding 30-sec video

Turn insight into action.

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.

Standard search

- Overview
- Copilot steps
- Referenced response
- Show all references
- Reference details and Trust Cards
- Find collaborators
- Find funding
- Export referenced response**

# Report and diagram

Turn a referenced response into a shareable report with linked citations for traceability

Generate a short report from the current conversation and its referenced sources. Add a diagram when requested, and keep citations linked to the original sources for inspection. Export/download the report when available.

Produce a stakeholder-ready brief you can share for review and decisions, while keeping claims traceable for compliance and business-case discussions.

## Workflow

- Ask a follow-up: “Create a report for my team based on the above with a diagram”
- Review the report and tighten scope with one constraint if needed
- Verify key claims via citations → Reference details → Trust Cards
- Download, then share with stakeholders

The screenshot displays two side-by-side panels from the LeapSpace interface. The left panel, titled 'GLP-1 receptor agonists for weight management', shows a report titled 'Current Funding Opportunities for GLP-1RA and Obesity Research'. It includes sections for 'Latest Research Insights', 'Efficacy in Non-Diabetic Adults', 'Mechanisms', 'Safety', and 'Additional benefits'. Below these sections is a table of 'Pioneering Researchers' with columns for Researcher, Affiliation, Focus, Key Contribution, and Citation. The right panel, titled '5. Diagram - Research to Funding Pipeline', shows a vertical flowchart with steps: 'GLP-1RA Research Insights', 'Pioneering Researchers', 'Collaborative Opportunities', 'UK/Europe Funding Calls', 'Corporate-University Project', and 'Clinical & Commercial Impact'. Below the diagram are sections for 'Next Steps' and 'Follow-up Suggestions'.

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Ask for a one-page brief + diagram, then verify 1-2 claims before you send.



Generate research reports and share your findings visually with LeapSpace



# Deep research

*“LeapSpace was created with researchers in mind, which means I have more trust in it. It helps refine where I want to go in my research, validates certain directions to explore, and makes it easier to learn outside of my domain. LeapSpace has also propelled me to a point in my reading I wouldn’t reach otherwise. I run Deep research reports in the background and then save them for my train journey.”*

**Paul Preuschoff**

Human Computer Interaction (HCI) Researcher,  
RWTH Aachen University

# Deep research for complex questions

Multi-agent mode that produces a structured, referenced report with scope, assumptions, and limitations

Deep research decomposes your question and runs a multi-agent workflow across Scopus records and available full text. It iterates through search, reading, and refinement, then uses a meta-analysis step to integrate perspectives and surface evidence gaps before writing a structured, referenced report.

For R&D teams, the steps panel is the traceability layer: it makes the workflow reviewable, helps explain how the report was built, and supports critical thinking by showing what was searched and what was found.

## Workflow

- Switch Deep research on before you run the query
- Ask a complex, multi-part question (add one constraint if needed)
- Review Deep research steps as it plans and runs
- Start with the report's Quick Reference / Key findings
- Verify key claims via citations → Reference details → Trust Cards
- Export or share the report when available

## Discover *deeper* insights

Powered by Scopus data and ScienceDirect full-text

Develop biocompatible click reactions in aqueous/biological media (CuAAC and SPAAC) that don't disrupt native processes. Use them to functionalize biomolecules and build drug-delivery systems (B-cyclodextrin-dendron hybrids, modified curcumin) to boost solubility, stability, and targeted delivery. Validate scalability across materials science and pharma.

Deep Research



Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Add one constraint (time window, geography, method) to reduce noise, then verify the key claims you will reuse.



[Watch Deep research in action](#)

## Deep research

Deep research overview

Deep research steps

Deep research report

Show all references

Reference details and Trust Cards

Export Deep research report

# Deep research steps

A running log of planning, retrieval, iteration and report writing

Deep research steps shows what Deep research actually ran for your query, in real time: planning the research approach, generating sub-queries, running searches, reporting sources found, coordinating phases, then moving through meta-analysis and report writing.

For R&D teams, this is the traceability layer: it makes the workflow reviewable and helps explain how the report was built before you reuse claims in decisions or documents.

## Workflow

- Run a Deep research query and open Deep research steps
- Review planning and sub-queries
- Scan progress signals (sources found, phases, completion)
- Verify key claims via citations → Reference details → Trust Cards
- If the run drifts, add one constraint and rerun

The screenshot displays the 'Deep research steps' interface. At the top, a blue box contains the query: 'Develop biocompatible click reactions in aqueous/biological media (CuAAC and SPAAC) that don't disrupt native processes. Use them to functionalize biomolecules and build drug-delivery systems (β-cyclodextrin-dendron hybrids, modified curcumin) to boost solubility, stability, and targeted delivery. Validate scalability across materials science and pharma.' Below this, a progress bar indicates 'Processed for 2 min 18 sec'. A 'View as PDF' button is visible. The main content area is titled 'Biocompatible Click Chemistry in Aqueous Media: Functionalization Strategies and Scalable Drug-Delivery Systems'. It includes a 'Quick Reference' section with a 'Key Findings Table'.

Theme	Key insights	Supporting citations
Biocompatible Click Reaction Optimization	CuAAC and SPAAC are optimized for aqueous/biological media via ligand/catalyst design, ultrasound, and surfactants to minimize toxicity and preserve native processes.	1 2 3 4
Advanced Catalyst systems	Novel ligands (e.g., ligand 6, PNH-type pincer) and heterogeneous supports reduce copper leaching and ROS, enabling safe, efficient CuAAC in live cells.	5 6 7
Functionalization of biomolecules	CuAAC and SPAAC enable site-specific, orthogonal, and multifunctional bioconjugation, including genetic code expansion for ncAAs.	1 8 9
Drug-Delivery System Design	β-cyclodextrin-dendron hybrids and modified curcumin, via click chemistry, enhance solubility, stability, and targeted delivery (e.g., folate conjugation).	10 11

Below the table is a text input field labeled 'Ask a follow-up question' with a submit button.

On the right side of the interface, a vertical log of steps is shown:

- Deep research steps
- copper catalysts in continuous processes for your question.
- I've found 20 sources related to how cross-linking density in β-cyclodextrin nanosponges affects curcumin release kinetics.
- I've found 20 sources related to how β-cyclodextrin-dendron hybrids stabilize the diketone tau.
- I've found 20 sources related to how automated flow chemistry platforms work with CuAAC and SPAAC to improve reaction conditions.
- I've found 20 sources on the latest techniques for using clickable non-canonical amino acids in genetic code expansion.
- I've found 20 sources related to optimizing ultrasound parameters for CuAAC reaction rates while maintaining biomolecule integrity.
- I've found 20 sources related to the challenges and solutions for scaling copper catalysts in continuous CuAAC processes.
- I've found 20 sources related to the roles of novel ligands and PNH-type pincer complexes in reduction processes.
- I've finished the research for depth 3 and added the findings to four topics.
- I'm reviewing the findings from depth 3 and planning the next steps for our research.
- I've reached the maximum research depth, so I'm finishing up the research process now.
- I'm aggregating the research findings.
- I've completed a meta-analysis on the research findings.
- I'm planning the report structure.
- I've completed the report structure.
- I'm starting to write the report.
- I've completed the research process.

*Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.*



## Power user tip

If steps show many parallel topics, add one constraint (time window, method, domain) before rerunning; if steps show limited evidence, broaden the query and rerun.

## Deep research

Deep research overview

Deep research steps

Deep research report

Show all references

Reference details and Trust Cards

Export Deep research report

# Deep research report

A structured, referenced report with quick findings, scope, assumptions, limitations and next steps

Deep research report is designed to support critical thinking by making scope and limits explicit, surfaces evidence gaps and contradictions where present, and stays traceable to sources.

For corporate R&D, it creates a stakeholder-ready artifact you can review, defend and share for due diligence and decision-making.

## Workflow

- Start with Quick Reference / Key findings to confirm you are in scope
- Read the Direct Answer, then check Study Scope (time period, disciplines, methods)
- Review Assumptions & Limitations before reusing any claim
- Open citations → Reference details → Trust Cards for the claims you will share
- Use Suggested Further Research to plan the next experiments or searches
- Export via View as PDF when you need to circulate the report

Show deep research steps - Processed for 1 min 55 sec

Deep research report Biocompatible click... View as PDF

This report may contain inaccuracies. Please verify the information independently.

### Biocompatible Click Reactions for Functional Biomolecule Modification and Advanced Drug-Delivery Systems: From Mechanistic Insights to Scalable Applications

Quick Reference

Key Findings Table

Theme	Key Insights	Supporting Citations
<b>Biocompatible click Reactions</b>	SPAAC is inherently bioorthogonal and inert in biological media; CuAAC can be rendered biocompatible via advanced ligand design and heterogeneous catalysts.	1 2 3 4 5 6
<b>Ligand/Catalyst Innovations</b>	Ligand (6), PNN-type pincer complexes, and immobilized copper-ligand systems reduce copper toxicity and ROS generation, enabling safe CuAAC in live cells.	3 4 7 8 9
<b>Biomolecule Functionalization</b>	CuAAC and SPAAC enable high-yield, selective, and bioorthogonal conjugation of peptides/proteins, preserving biological activity. Triazole linkages stabilize structure and enhance bioactivity.	10 11 12 13 14 15
<b>Drug-Delivery Systems</b>	β-cyclodextrin-dendron hybrids and modified curcumin systems improve solubility, stability, and targeting. Dendronization and folic acid conjugation enhance loading, release, and tumor targeting.	16 17 18 19
<b>Scalability</b>	Challenges include reproducibility, copper speciation, and catalyst recyclability. Solutions involve process controls, metal-free reactions, and integration with 3D bioprinting.	20 21 22 23

Direct Answer

Biocompatible click reactions (CuAAC and SPAAC) can be optimized for aqueous/biological media through advanced ligand design and catalyst immobilization to reduce copper toxicity, while maintaining high efficiency and bioorthogonality for biomolecule functionalization. These optimized reactions are successfully applied in drug-delivery systems—specifically β-cyclodextrin-dendron hybrids and modified curcumin formulations—that improve solubility, stability, and targeting. Scalability for industrial applications requires addressing reproducibility, controlled copper speciation, and integration with advanced fabrication techniques like 3D bioprinting [1-3].

Study Scope

- **Time Period:** 2018-2024
- **Disciplines:** Chemical biology, materials science, pharmaceutical engineering
- **Methods:** Meta-analysis of empirical studies, mechanistic investigations, synthetic chemistry, in vitro/in vivo validation, process engineering

Assumptions & Limitations

- Most findings are based on controlled laboratory conditions; translation to clinical/industrial scale may require further optimization.
- Copper toxicity and ROS generation are mitigated but not fully eliminated in all heterogeneous catalyst systems.
- SPAAC reagents' synthesis can be time-consuming and costly.
- Integration with advanced manufacturing (e.g., 3D bioprinting) is promising but not yet fully standardized for clinical use.

Suggested Further Research

- Complete elimination of copper ion leaching and ROS generation in heterogeneous Cu(I) catalysts.
- Optimization of stimuli-responsive click materials for scalable manufacturing.
- Machine learning-guided design of SPAAC reagents for improved kinetics and selectivity.
- Systematic clinical translation studies for drug-delivery systems based on β-cyclodextrin-dendron hybrids and modified curcumin.

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Use one constraint (time window, method, domain) to steer the next run.



See Deep research in action

Deep research

Deep research overview

Deep research steps

Deep research report

Show all references

Reference details and Trust Cards

Export Deep research report

# Show all references

Review the full evidence set behind the Deep research report and drill down to inspect sources

Show all references opens the full list of sources cited in the Deep research report (~70–90). Each item links to source details so you can open abstracts and available full text.

Scan the evidence set in minutes to confirm coverage, spot gaps, and decide what to open next before you reuse claims. This reduces manual cross-checking and keeps evidence selection traceable in briefs, protocols, and decision notes.

## Workflow

- Click Show all references in the report
- Scan the list for coverage, recency, relevance
- Open 2–3 central sources first
- Use Reference details and Trust Cards to inspect passages
- Open full text when methods and limitations matter; abstract for screening

The screenshot displays the LeapSpace interface. On the left, a research report titled 'Biocompatible click reactions for drug delivery' is visible, with sections for 'Real-World Implications' and 'Synthesis'. The 'Real-World Implications' section lists key findings in Pharmaceuticals, Materials Science, and Clinical Translation. The 'Synthesis' section discusses progress in optimizing click reactions. On the right, an 'All references' panel shows a list of cited sources, including articles from Scopus and full-text documents, each with options to view abstracts, full texts, or Scopus documents.

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Open one source that supports the main claim and one that frames limits or alternatives.

# Inspect the source behind a claim

Reference details gives the excerpt and context for each citation, so you can verify before reuse

Citations open Reference details with source metadata plus Excerpts and Abstract, and links to View full text or View Scopus document when available.

For R&D teams, this is the verification step before reuse in briefs, protocols, and decision notes: inspect the excerpt in context, then open full text when methods and limitations matter.

## Workflow

- Click a citation in the Deep research report
- Review source metadata and available links (full text / Scopus record)
- Inspect Excerpts first; switch to Abstract for context
- Open full text when methods and limitations matter
- Repeat for the claims you plan to share

**Planned** (roadmap): Claim Radar to widen verification beyond a single citation (support / neutral / contradict). Stay tuned.

Biocompatible click reactions for drug delivery

Synthesis  
Click chemistry enables the modular synthesis of  $\beta$ -cyclodextrin-dendron hybrids and modified curcumin systems, significantly improving solubility, stability, and bioactivity for drug delivery [17] [67].

Dendronization Effects on Loading Capacity and Release Kinetics

- **Porosity and Surface Area:** Dendronization/cross-linking increases curcumin loading by enhancing carrier porosity [69].
- **Controlled Release:** Dendronized systems enable sustained and pH-responsive release, crucial for targeted delivery to tumor microenvironments [70] [71].
- **Carrier Modification:** Ethylene diamine modification increases loading efficiency and solubility [72].
- **Release Kinetics:** Faster release under acidic conditions due to polymer swelling and weakened drug-polymer interactions [70] [73].

Synthesis  
Dendronization is a key strategy for enhancing drug loading and enabling controlled, stimuli-responsive release in advanced drug-delivery systems [69] [70].

Targeted Delivery: Folic Acid-Conjugated Nanoparticles vs. Nanosponges

System	Targeting Efficiency	Drug Loading	Release Kinetics	Therapeutic Capability
FA- $\beta$ -CD Nanoparticles	High (folate receptor-mediated)	Moderate	Fast, pH-responsive	Limited
FA-Magnetic Nanosponges	High (folate + magnetic targeting)	High	sustained, pH-sensitive	MRI contrast, imaging

• **FA- $\beta$ -CD Nanoparticles:** Enhanced tumor targeting, pH-responsive release, significant in vivo antitumor activity [17].

• **FA-Magnetic Nanosponges:** Multifunctional, combining targeted delivery, imaging, and controlled release [18].

Reference details

Full text

Improved curcumin loading, release, solubility and toxicity by tuning the molar ratio of cross-linker to  $\beta$ -cyclodextrin

Ghollbegloo, E. 71; Morfezazadeh, T. 71; Salehian, F. 71; Amanlou, M. 71; Khoobi, M. 71

Carbohydrate Polymers 71 • 2019

93 citations

View full text 71 View Scopus document 71

Excerpts Abstract

A novel  $\beta$ -cyclodextrin-based nanosponge (CDNS) was proposed as curcumin (CUR) delivery system improving pharmacokinetics and anticancer activity of CUR. The effect of molar ratio of EpiCon (EPI) as cross-linker and  $\beta$ -cyclodextrin ( $\beta$ CD) on the porosity, surface area swelling ratio, CUR solubility and loading capacity, rate of drug release and selective toxicity of the CDNSs was fully investigated. The high degree of cross-linking led to the formation of mesoporous CDNS having high specific surface area and high loading capacity. All CUR-free CDNSs showed no toxicity against MCF 10A and 4T1 cells as normal and cancerous cells, respectively. While CDNSs-CUR exhibits selective toxicity against cancerous cells. In sum, high CUR aqueous solubility, significant loading and controllable release of the CUR, outstanding and selective toxicity against cancerous cells make CDNSs-CUR (EPI/ $\beta$ CD = 8) as promising candidate for further study in the cancer therapy.

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



## Power user tip

Verify one key claim per section before you share the report.

# Report and diagram

Create a shareable report from the conversation, with linked citations and an optional diagram

LeapSpace composes the report from the current conversation context and the referenced sources already retrieved, preserving linked citations as it formats sections and tables. When requested, it generates a diagram that summarizes the logic chain. Export/download the report when available.

For R&D users, this is the handoff artifact: a stakeholder-ready brief with recommendations and a diagram you can review and circulate, while keeping claims traceable for compliance and business-case decisions.

## Workflow

- Ask a follow-up: “Create a report for my team based on the above with a diagram”
- Review the report and tighten scope with one constraint if needed
- Verify key claims via citations → Reference details → Trust Cards
- Export/download when available, then share with stakeholders
- Capture next actions in your template (fund, partner, implement)

Biocompatible click reactions for drug delivery

Create a report for my team based on the above with a diagram

Collator steps >

### Biocompatible Click Reactions and Drug-Delivery Systems

Here's a synthesized report for your team based on our previous findings, with an included diagram for clarity.

Report: Biocompatible Click Reactions for Biomolecule Functionalization and Drug Delivery

1. Overview

Biocompatible click reactions—**CuAAC** (copper(I)-catalyzed azide-alkyne cycloaddition) and **SPAAC** (strain-promoted azide-alkyne cycloaddition)—enable high-yield, selective, and bioorthogonal conjugation in aqueous/biological media without disrupting native processes. Optimizations in **ligand design**, **catalyst immobilization**, and **reaction conditions** have expanded their safe use in live-cell and in vivo systems, supporting applications in **drug delivery**, **materials science**, and **pharma** (1, 2, 3, 4, 5, 6, 7, 8).

2. Key Advances

Theme	Key insights	Citation
<b>SPAAC</b>	Copper-free, inherently bioorthogonal, ideal for in vivo use; avoids ROS and metal toxicity.	(1) (2) (3)
<b>CuAAC Optimization</b>	Advanced ligands (e.g., PNH-type pincer, water-soluble chelators) stabilize Cu(I), reduce toxicity, and improve kinetics.	(3) (4) (5) (6)
<b>Heterogeneous Catalysts</b>	supported Cu(I) systems (NHCs, chitosan, nanocrystals) improve recyclability and reduce leaching.	(5) (6) (7) (8) (9)
<b>biomolecule functionalization</b>	Triazole linkages enhance stability, bioactivity, and proteolytic resistance.	(9) (10) (11) (12) (13)
<b>Drug Delivery Systems</b>	$\beta$ -cyclodextrin-dendron hybrids and modified curcumin improve solubility, stability, and targeting.	(14) (15) (16) (17) (18) (19)
<b>Scalability</b>	Requires control of copper speciation, reproducibility, and integration with 3D bioprinting.	(20) (21) (22) (23)

3. Recommended Next Steps

1. **Catalyst Development:** Eliminate copper leaching entirely in heterogeneous CuAAC.
2. **SPAAC Reagent Engineering:** Use ML-guided design for faster, more selective cyclooctynes.
3. **Clinical Translation:** Systematic in vivo studies for  $\beta$ -CD-dendron and curcumin systems.
4. **Manufacturing Integration:** Standardize click-based biolinks for clinical-grade 3D bioprinting.

Figure 1: Workflow from click reaction optimization to functionalized biomolecules and advanced drug

Disclaimer: LeapSpace interface shown for illustration; actual results may vary. Screenshots may be partial.



### Power user tip

Ask for a one-page brief + diagram, then verify 1–2 key claims before sharing.



LeapSpace visualization:  
See it in action

# Core content



<b>Content coverage</b>	Content curated by human experts	Full text: depth	Abstracts and metadata: breadth	Full text and abstracts and metadata in LeapSpace	Author and funding entities in LeapSpace
-------------------------	----------------------------------	------------------	---------------------------------	---	--

# Publisher-neutral, high-quality content and data

LeapSpace draws from the most comprehensive collection of trusted scientific content

## Full text

18+ million peer-reviewed full-text articles and books from **ScienceDirect**, and licensed subscription and open access content from other leading publishers and societies, including **Emerald Publishing, IOP Publishing, NEJM Group, and Sage**, with more publishers joining.

## Abstracts and metadata

The world's largest collection of research abstracts from **Scopus** (100+ million records from 7,000+ publishers), including **21.9+ million author profiles** and **94,000 organization profiles**.

## Funding opportunities

**Curated global funding** data, including 45,000+ active and recurring opportunities from 16,000+ government and private funders.

- Content is supported by human oversight, including peer review, the independent [Scopus Content Selection and Advisory Board](#) and a new independent AI Advisory Board. [Learn more about LeapSpace's trust and security features](#). Results are ranked by relevance with a small boost for recency, regardless of publisher ownership or discipline.
- Content coverage continuously expand, publisher neutrality is enforced. Users can also upload their own documents to support analysis. Retracted articles are excluded.

 [What is peer review?](#)

 [What are research integrity checks?](#)

# Human oversight throughout

Responsible AI, grounded in trusted content, with researchers in control

**Peer review and editorial oversight**  
Journal and book publishing process

Scopus Content Selection and Advisory Board (CSAB)  
Independent selection and re-evaluation for Scopus-indexed sources

Independent AI Advisory Board Oversight for transparency, explainability, and publisher neutrality



## Human expertise is embedded across LeapSpace, including:

- Content curation and selection
- Model evaluation and quality assurance
- Ongoing validation and governance

**LeapSpace is designed to reinforce, not replace, human research judgment.**



[Learn more about transparency and oversight in Leap Space](#)

# Full text: depth you can verify

Methods, results, figures, and limitations across documents

## Regular article

Reports original methods, data and results



[Induction of Pluripotent Stem Cells by Defined Factors](#)  
DOI: 10.1016/j.cell.2006.07.024  
Landmark iPSC reprogramming study (Nobel context)

## Review article

Synthesizes evidence across studies, consensus and gaps



[Hallmarks of Cancer: The Next Generation](#)  
DOI: 10.1016/j.cell.2011.02.013  
Life sciences · Highly cited review that frames consensus and gaps

## Book chapters

Authoritative background, definitions, and stable reference



[Alzheimer's disease \(Chapter 13\)](#)  
DOI: 10.1016/B978-0-12-804766-8.00013-3  
Life sciences · Reference chapter for definitions and clinical context

## Short communications

Brief report of a focused new finding



[A model to predict flood loss in mountain areas](#)  
DOI: 10.1016/j.envsoft.2019.03.026  
Engineering and energy · Short communication with methods and results in brief

## Short reviews

Compact synthesis with key references to follow



[Layered perovskite materials: key solutions for highly efficient and stable perovskite solar cells](#)  
DOI: 10.1088/1361-6633/ab9f88/IOP Publishing  
Energy and materials · Review synthesis for stability and efficiency

## Case reports


Single-case evidence for rare events or hypothesis generation



[Parry-Romberg syndrome: A case report and literature review](#)  
DOI: 10.1016/j.radcr.2024.02.053  
Life sciences · Rare event evidence for hypothesis generation

## Discussions

Scholarly commentary that critiques or clarifies findings



[Comment: A call for a novel approach](#)  
DOI: 10.1016/S2214-109X(25)00215-3  
Cross-disciplinary · Scholarly critique and interpretation

## Protocols

Step-by-step methods for implementation and fidelity



[Protocol: CRISPR/Cas9 genome editing in budding yeast](#)  
DOI: 10.1016/j.xpro.2022.101358  
Cross-disciplinary · Step-by-step method for implementation fidelity

## Perspective

Expert viewpoint that interprets evidence and highlights implications



[Brave New Genome](#)  
DOI: 10.1056/NEJMp1506446  
Life sciences · NEJM Perspective on genome editing governance



- Examples include Elsevier and other publishers and societies.
- Coverage varies by source and document type. Full text excludes conference reviews and errata.

Content coverage	Content curated by human experts	Full text: depth	<b>Abstracts and metadata: breadth</b>	Full text and abstracts and metadata in LeapSpace	Author and funding entities in LeapSpace
------------------	----------------------------------	------------------	--	---	--

# Abstracts and metadata: breadth you can scan

Abstracts, citation context, and linked entities for fast discovery and filtering

**Articles**  
Abstract and metadata for broad discovery and fast filtering



[Induction of Pluripotent Stem Cells by Defined Factors](#)  
DOI: 10.1016/j.cell.2006.07.024  
Life sciences · Landmark iPSC reprogramming study (Nobel context)

**Reports**  
Record for technical or policy outputs and benchmarks



[TFOS DEWS II pathophysiology report](#)  
DOI: 10.1016/j.jtos.2017.05.011  
Health sciences Consensus report used to frame definitions and mechanism

**Book chapters**  
Chapter-level record to target a concept inside a larger book



[Alzheimer's disease: An overview](#)  
DOI: 10.1016/B978-0-12-804766-8.00013-3  
Life sciences · Reference chapter for definitions and clinical context

**Conference papers**  
Conference record for early signals in fast-moving fields



[Deep Residual Learning for Image Recognition](#)  
Kaiming He, Xiangyu Zhang, Shaoqing Ren, Jian Sun  
Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2016, pp. 770-778  
DOI: 10.1109/CVPR.2016.90  
Technology · Landmark · Introduced ResNet (CVPR 2016)

**Data papers**  
Record describing a dataset, methods, and reuse conditions



[High-resolution datasets for urban heat vulnerability assessment in urbanized areas of the Netherlands](#)  
DOI: 10.1016/j.dib.2025.111525  
Engineering and energy · Data paper with dataset access and reuse conditions

**Reviews**  
Review record to find authoritative syntheses quickly




[USPs and non-coding RNAs: Unraveling their interplay within tumor microenvironment for targeted cancer therapy](#)  
DOI: 10.1016/j.phrs.2025.107853  
Pharmaceutical research · Landmark

**Short surveys**  
Compact record that maps a field briefly



[SSS-PR: A short survey of surveys in person re-identification](#)  
DOI: 10.1016/j.patrec.2020.12.017  
Technology · Short survey mapping a fast-moving field

**Funding opportunities**  
Linked opportunities that open on the funder source.



Title: [Takeda Science Foundation](#)  
Funder website: [Takeda Science Foundation](#)  
Funding · Funder profile with opportunity link (Funding opportunities link to the funder source. Verify eligibility and deadlines at the source.)

**Author profile**  
Linked profiles for finding experts and institutions fast




Author: [Shinya Yamanaka](#)  
Life sciences · Verify expertise via matching documents and affiliations  
Organization: [Center for iPS Cell Research and Application \(CiRA\), Kyoto University](#)  
Life sciences · Institution profile linked to publications and authors



- Records support broad discovery and filtering across publishers. Use full text to verify methods and limitations.
- Coverage varies by source and document type. Tiles show common record types, not an exhaustive list.

# Full text and abstracts in LeapSpace

Use full text to verify methods and limitations. Use Scopus records to scan



### In LeapSpace

- Full text: inspect methods, results, figures, and limitations
- References and Trust Cards help you verify claim-to-source alignment

### In LeapSpace


(publisher-neutral)

- Scopus record: scan abstracts, metadata, and citation context
- References and Trust Cards help you verify claim-to-source alignment

Induction of Pluripotent Stem Cells by Defined Factors

DOI: 10.1016/j.cell.2006.07.024

Life sciences · Landmark iPSC reprogramming study (Nobel context)



### Full text

- Version of record with methods, data, figures, and limitations
- Best for verification and defensible reuse
- Full text may open on the publisher platform (access varies by subscription).

Induction of Pluripotent Stem Cells by Defined Factors

DOI: 10.1016/j.cell.2006.07.024

Life sciences · Landmark iPSC reprogramming study (Nobel context)



### Scopus record

- Abstract + metadata + citation context
- Best for discovery, filtering, citation trails, and author or affiliation context

Induction of Pluripotent Stem Cells by Defined Factors

DOI 10.1016/j.cell.2006.07.024


Life sciences · Landmark iPSC reprogramming study (Nobel context)



- Copilot may cite Scopus records or full text, depending on what supports each statement
- Deep Research may cite Scopus records or full text, depending on what supports each statement

# Author and Funding entities in LeapSpace

Use different verification rules for profiles and funding



In LeapSpace

### Find collaborators

- Profiles link to matching documents

### Verify

- Open matching documents and affiliations
- Use metrics as signals, not proof



Author: [Shinya Yamanaka](#)

Life sciences - Verify expertise via matching documents and affiliations

Organization: [Center for iPS Cell Research and Application \(CiRA\), Kyoto University](#)


Life sciences - Institution profile linked to publications and authors

### Author and organization profiles

- Evidence about expertise is derived. Verify via matching documents.



- Copilot may cite Scopus records or full text when supporting statements
- Deep Research may cite Scopus records or full text when supporting statements



In LeapSpace

### Find funding

- Opportunity data is actionable, not evidence

### Verify

- Open the funder page for eligibility, deadlines and amounts



### Funding opportunities

- Opportunity data is actionable, not evidence. Verify at the source.

